SAFE SUPPLY

Safe Supply

We are invested in providing the safest supply of natural and synthetic psychedelics to the international market.

An In Demand Medicinal Alternative

Populations across the world are realizing that psilocybin and synthetic psychedelics can help alleviate severe depression and end-of-life distress, among many other palliative and non-palliative conditions.

Optimi is the leader of Safe Supply in Canada. Our facility produces the purest natural and synthetic pharmaceutical-grade investigational drugs to authorized patients and physicians in Canada with Section 56 Exemptions or permission under the Special Access Program (SAP). We also supply eligible academic researchers and clinical trials advancing the interest and understanding of psychedelic science as an innovative medical component to alleviate mental suffering.

Optimi Supplied Drugs:

  • EU-GMP psilocybin:

      • Bulk form API

      • Dried biomass

      • Dried biomass encapsulated (standardized to desired strength)

      • Extract (pure or encapsulated)

      • Isolate

  • EU-GMP 3,4-methylenedioxy-methamphetamine (MDMA)

Why Safe Supply Matters

"There's an emerging consensus to do more to reverse this devastating trend."

- Hon. Carolyn Bennett,
Canadian Minister of Mental Health and Addictions
Optimi is committed to building a healthier world, and we believe for that to happen people need access to the safest supply of medical psychedelics possible. Safe supply would protect the integrity of the psychedelic supply chain by guaranteeing all licensed dealer’s operate under the strictest GMP controls and standards. 

Reasons why safe supply is needed today:
    • The grey and black markets are thriving online and in neighbourhoods across Canada. One way to combat this health and safety risk is to allow for licensed dealers to provide directly to consumers.

    • Many of the illegal drugs bought off the street risk being tainted with fentanyl, which is between 50 to 100 times stronger than morphine. Heroin, cocaine, oxycodone, and many other drugs found on the street can be cut with fentanyl, in powder, liquid, or pill form, rendering them even more toxic. You can’t see it, smell it or taste it.

    • Illegal drugs on the dark web only emerged a decade ago but major ones are now worth at least US$ 315 million in annual sales. Rapid technological innovation, combined with the agility and adaptability of those using new platforms to sell drugs and other substances, is likely to usher in a globalized market where all drugs are more available and accessible everywhere. This, in turn, could trigger accelerated changes in patterns of drug use and entail public health implications.

    • Globally, over 11 million people are estimated to inject drugs, half of whom are living with Hepatitis C. Opioids continue to account for the largest burden of disease attributed to drug use.

    • Self-medicating with psychedelics is risky.

    • Clinical trials take time to assess consistent dosing when taking natural psilocybe mushrooms. That data does not currently exist.

    • Therapists and patients looking to utilize psychedelics are unable to measure levels of natural psilocybin contained in mushrooms.

    • Section 56 exemption holders would have access to a regulated market in which to purchase mushrooms.

Why Safe-Supply?

Risks of not having Safe Supply:

  • Supply: Toxicity of Supply Designer Drugs
  • Quality of Ingredient Contamination
  • Drug Mixing
  • Poisonous
  • Microbial Adulterants
  • Supply Shortage
  • Lost Tax Revenue
Benefits of Safe Supply:

  • Healthy Patient Outcomes
  • EU-GMP
  • Safety
  • Data Efficacy
  • Quality Control
  • Tax Revenue
  • Science Education
  • Set & Setting
  • Therapeutic Continuity

Safe Supply for Patients

Optimi produces the safest, most consistent, and purest natural psilocybin mushrooms available to authorized patients and physicians with Section 56 Exemptions or permission under the Special Access Program. We ensure quality to patients seeking therapeutic relief under the gradually-expanding prescription models for psilocybin.

Safe Supply for Researchers

Studies from leading institutions are establishing the efficacy of psilocybin as an alternative treatment for various mental health disorders. The US Food and Drug Administration has granted a Breakthrough Therapy designation to psilocybin.

Health Canada has come forward in support of the ongoing research, but recognizes the lack of studies using natural psilocybin and psilocin. Further progress is possible only with GMP-standardized natural psilocybin.

Optimi is working with Health Canada to provide that research using safe and standardized doses of natural psilocybin.

Optimi’s commercial facility can provide up to 5000 kilograms of dried psilocybin mushrooms, capable of producing 10 kilograms of psilocybin and 100 grams of psilocin at the highest operational standards of safety and quality, to supply authorized private and public sector researchers.

Subscribe to our newsletter

Get updates directly to your inbox.